Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication.
Any strategy for curing HIV infection must include a method to eliminate viral-infected cells. Based on our earlier proof-of-principle results targeting HIV-1 infected cells with radiolabeled antibody (mAb) to gp41 viral antigen, we embarked on identifying a suitable candidate mAb for preclinical de...
Main Authors: | Ekaterina Dadachova, Scott G Kitchen, Gregory Bristol, Gayle Cocita Baldwin, Ekaterina Revskaya, Cyril Empig, George B Thornton, Miroslaw K Gorny, Susan Zolla-Pazner, Arturo Casadevall |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3302885?pdf=render |
Similar Items
-
Correction: Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication
by: Ekaterina Dadachova, et al.
Published: (2012-01-01) -
Correction: Pre-Clinical Evaluation of a Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication.
by: Ekaterina Dadachova, et al.
Published: (2012-01-01) -
Immunoprophylaxis against mother-to-child transmission of HIV-1.
by: Miroslaw K Gorny, et al.
Published: (2006-07-01) -
Combination of anti-retroviral drugs and radioimmunotherapy specifically kills infected cells from HIV infected individuals
by: Dina Tsukrov, et al.
Published: (2016-09-01) -
Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects.
by: Evgeny Shmelkov, et al.
Published: (2011-01-01)